Seven plus eight makes six for Globus
The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
AHA 2022 – History repeats for Medtronic
The company’s renal denervation system has failed in a crucial late-stage trial, just as an earlier version did eight years ago.
